ストックスクリーナーアプリを入手
65.04
2.63%
-1.76
アフターアワーズ：
65.52
0.48
+0.74%
前日終値:
$66.80
開ける：
$67
24時間の取引高:
1.73M
Relative Volume:
0.92
時価総額：
$7.95B
収益：
$18.47M
当期純損益:
$-589.53M
株価収益率:
-12.37
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
+7.97%
1か月 パフォーマンス:
+0.62%
6か月 パフォーマンス:
+89.57%
1年 パフォーマンス:
+54.20%
1日の値動き範囲:
$64.64
$67.89
1週間の範囲:
$61.00
$67.89
52週間の値動き範囲:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.04 | 8.17B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - Yahoo! Finance Canada
Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX) - The Globe and Mail
Cytokinetics announces recipients of its eighth annual communications grant program - marketscreener.com
Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program - TradingView
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - The Manila Times
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aug Selloffs: Is Cytokinetics Incorporated a potential multi baggerJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Bank Watch: Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bank of America Securities Remains a Hold on Cytokinetics (CYTK) - The Globe and Mail
Surprises Report: Is Cytokinetics Incorporated stock a good pick for beginners2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Finviz
Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating - marketscreener.com
Truist Securities Raises Price Target for CYTK with Buy Rating | - GuruFocus
2026 Biotech Hot Picks: Top 7 Stocks to Watch | Truist Analysis - techi.com
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential - DirectorsTalk Interviews
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares - MarketBeat
New Highs: Whats the RSI of Cytokinetics Incorporated stockQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Will Cytokinetics Incorporated outperform its industry peersShort Setup & Stock Portfolio Risk Management - mfd.ru
J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Diagnostic and Interventional Cardiology
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News - GuruFocus
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Barclays - MarketBeat
Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM - Yahoo Finance
CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus
Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance
How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Truist Securities reiterates Buy rating on Cytokinetics stock at $84 target - Investing.com Canada
Cytokinetics launches first product, Myqorzo - The Pharma Letter
Analyst Upgrade: What is the long term forecast for Cytokinetics Incorporated stock2025 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM) - MultiVu
Cytokinetics (CYTK) Launches HCM Awareness Campaign with Olympic Star - GuruFocus
Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan
Cytokinetics Announces U.S. Launch of MYQORZO™ (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
New heart drug MYQORZO reaches U.S. patients, but with strict safety rules - stocktitan.net
US FDA caps 2025 with December high of 27 drug approvals - BioWorld MedTech
Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - 富途资讯
Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - marketscreener.com
Bull Bear: What are HSPOs earnings expectationsLayoff News & Capital Efficiency Focused Strategies - baoquankhu1.vn
RBC Capital Reiterates Outperform Rating for Cytokinetics (CYTK) - GuruFocus
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 05 '26 |
Sale |
61.93 |
15,000 |
928,950 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 02 '26 |
Option Exercise |
37.63 |
886 |
33,340 |
51,326 |
| Callos Andrew | EVP, Chief Commercial Officer |
Feb 02 '26 |
Sale |
62.10 |
886 |
55,021 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 05 '26 |
Option Exercise |
23.26 |
15,000 |
348,900 |
65,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 05 '26 |
Sale |
60.28 |
15,000 |
904,200 |
50,440 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 02 '26 |
Option Exercise |
37.63 |
885 |
33,303 |
51,325 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jan 02 '26 |
Sale |
62.62 |
1,798 |
112,585 |
50,440 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):